Opendata, web and dolomites

VANGUARD SIGNED

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VANGUARD project word cloud

Explore the words cloud of the VANGUARD project. It provides you a very rough idea of what is the project "VANGUARD" about.

safety    protection    vivo    social    constructs    overexpress    producing    implantability    mechanical    scientists    langerhans    outgrowth    human    infinite    biocompatibility    haecs    model    translational    clinical    immunomodulatory    xenogeneic    confer    epithelial    islet    sources    ethical    cells    therapeutic    boecs    consists    worldwide    managed    endothelial    hydrogel    cd47    haec    urgent    atmp    million    potency    genome    reconstituted    ngo    graft    insulin    molecules    smes    delivered    utilizing    hla    membrane    diabetic    assembling    blood    edited    therapies    larger    pancreas    stem    mice    inflammatory    pd    extracellular    immune    disease    suffer    locally    vanguard    chronic    majority    release    completion    medicinal    transplantation    limited    diabetes    organoids    beta    accessibility    destruction    implantation    expertise    individuals    rapid    academic    vitro    cell    forty    construct    vast    amniotic    complications    replacement    components    l1    therapy    matrix    revascularization    patients    bioartificial    devastating    anti   

Project "VANGUARD" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITE DE GENEVE 

Organization address
address: RUE DU GENERAL DUFOUR 24
city: GENEVE
postcode: 1211
website: www.unige.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 6˙844˙625 €
 EC max contribution 6˙844˙625 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2019-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITE DE GENEVE CH (GENEVE) coordinator 1˙995˙946.00
2    OSPEDALE SAN RAFFAELE SRL IT (MILANO) participant 1˙049˙500.00
3    UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO IT (VERCELLI) participant 936˙875.00
4    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 804˙375.00
5    KUGELMEIERS AG CH (ERLENBACH) participant 701˙250.00
6    UNIVERSITE LYON 1 CLAUDE BERNARD FR (VILLEURBANNE CEDEX) participant 523˙812.00
7    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 393˙116.00
8    ACCELOPMENT AG CH (ZUERICH) participant 384˙750.00
9    EUROPEAN SOCIETY FOR ORGAN TRANSPLANTATION NL (AMSTERDAM) participant 55˙000.00

Map

 Project objective

Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies (pancreas or islet of Langerhans transplantation). There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients. The VANGUARD project aims to deliver an Advanced Therapeutic Medicinal Product (ATMP) of high translational potential, with properties of increased functionality and implantability and protection from immune destruction. We will construct a bioartificial pancreas by assembling insulin- producing organoids, composed of islet cells, human amniotic epithelial cells (hAEC) and blood outgrowth endothelial cells (BOECs), into an amniotic membrane-derived hydrogel. Components of the amniotic membrane will provide extracellular matrix and mechanical protection and confer their well-defined anti-inflammatory and immunomodulatory properties to the constructs. hAECs will be genome-edited to overexpress and locally release immunomodulatory molecules (HLA-G, HLA-E, CD47 and PD-L1) and endothelial cells will enhance graft revascularization. Functionality, biocompatibility, potency and safety of the bioartificial pancreas will be assessed in vitro and in vivo by implantation in mice reconstituted with a human immune system as pre-clinical model. The consortium consists of 5 academic institutions with leading scientists in their field, 2 SMEs and 1 NGO with expertise in ethical and social aspects of transplantation. The ATMP delivered upon completion of the project will provide a model for rapid development of a bioartificial pancreas, utilizing “infinite” sources of insulin-producing cells (stem cell-derived, xenogeneic), and available to all type 1 diabetic patients before they develop the devastating chronic complications of the disease.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VANGUARD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VANGUARD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More  

PD_Pal (2019)

Palliative care in Parkinson’s disease

Read More